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The solid state properties of pharmaceutical compounds have a decisive impact on
dosage form development, stability, and in vivo performance of the drug. Many pharma-
ceutical drugs are problematic per se due to their inappropriate physical and mechanical
properties and poor aqueous solubility. The micromeritic properties of drug particles,
such as shape and size, are of essential importance for the formulation of solid high-
-dose units (1). The particle size of poorly soluble drugs is always an issue due to its im-
pact on dissolution properties. Micronized drug particles (smaller than 10 mm) have a
large specific area and provide a way to improve the dissolution rate (2), but high en-
ergy input during the micronization process gives rise to increased free surface energy,
electrostatic tendencies, and thus poor flowability and/or compressibility of powders and
low bulk density (3), which makes them difficult to use in downstream processing in the
pharmaceutical industry such as direct tablet-making or capsule-filling processes. In ad-
dition, micronized drug substances tend to agglomerate and the increase in surface area
is not always reflected in improved dissolution (4).
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Spherical crystallization of drugs is the process of obtai-
ning larger particles by agglomeration during crystalli-
zation. The most common techniques used to obtain such
particles are spherical agglomeration and quasi-emulsion
solvent diffusion. Ammonia diffusion systems and cry-
stallo-co-agglomeration are extensions of these techniques.
By controlling process parameters during crystallization,
such as temperature, stirring rate, type and amount of sol-
vents, or excipient selection, it is possible to control the
formation of agglomerates and obtain spherical particles
of the desired size, porosity, or hardness. Researchers ha-
ve reported that the particles produced have improved
micromeritic, physical, and mechanical properties, which
make them suitable for direct compression. In some ca-
ses, when additional excipients are incorporated during
spherical crystallization, biopharmaceutical parameters in-
cluding the bioavailability of drugs can also be tailored.
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It is also known that the particle shape or »crystal habit« can influence the packing,
flowability, compressibility, dissolution, and sedimentation properties of pharmaceutical
powders (5, 6). For example, it has been demonstrated that symmetrically shaped crys-
tals of ibuprofen possess better compaction and flow properties than needle-shaped cry-
stals (7).
Physico-mechanical properties of crystals, such as melting point, solubility, true
density, dissolution profile, flowability and compactibility, can be modified by recrysta-
llizing the drug in different ways that affect the physical and chemical properties of for-
med particles. For example, ibuprofen crystals were grown from various solvents and,
by using various crystallization conditions, it was shown that various crystal forms with
various crystal shapes were obtained: cubic, needle-shaped, and plate-shaped crystals.
Differences in true density, flowing properties, and tabletability were determined for
these different particles (7, 8).
Poor physical and mechanical properties of drug particles have been traditionally
masked by various granulation methods, such as the conventional and widely used wet
granulation, which produces agglomerates with higher bulk density, better flowability,
and compressibility/compactibility. Most common techniques of wet granulation are
high-shear and fluid bed wet granulation, which generally involve mixing, atomization,
and spraying of granulation liquid on powders, drying steps, sieving, and so on. Both
agglomeration methods are energy-consuming process steps in dosage form production
and can impair the stability of moisture- or heat-sensitive drugs or can cause transfor-
mation of the physical form of drugs (9). Other agglomeration techniques, such as dry
granulation, hot-melt granulation, melt extrusion, spray congealing, or melt solidifica-
tion have been introduced in recent years, and have yielded some innovative solutions
for improving the physical and mechanical properties of drug particles; however, they
are still less economical than direct compression tableting.
In 1974, Kawashima and Capes (10) introduced the concept of obtaining larger par-
ticles by agglomeration during the crystallization step. Silica sand dispersed in agitated
carbon tetrachloride and agglomerated with calcium chloride aqueous solutions was
used as a model system. Some years later, Kawashima (11) used the »spherical crystalli-
zation« method for increasing the size of drug particles and defined it as »an agglomera-
tion process that transforms crystals directly into compact spherical forms during the
crystallization process.« Using this method, the precipitated crystals can be agglomer-
ated during the final synthesis step (recrystallization) into more or less spherical parti-
cles with sizes between 300 and 500 mm without any binders. This paper describes sphe-
rical crystallization methods and outlines the potential of the particles obtained.
SPHERICAL CRYSTALLIZATION
Crystallization is a process of forming solid crystals that occurs when molecules
start aggregating and precipitating from solution or melt. The rate and mechanisms by
which crystals are formed from liquid solutions are determined by many factors: ther-
modynamic (e.g., solubility, solid-liquid interfacial tension, solvent activity, temperature,
etc.), kinetic (e.g., supersaturation, molecular mobility, meta-stable zone width), and mo-
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lecular recognition (hydrogen bonds, non-covalent bonds, molecular networks). The dri-
ving force for crystallization is supersaturation, which describes the exceeding of the sa-
turated equilibrium concentration of solute (12–15). Supersaturation can be created by
increasing the solute concentration (solvent evaporation) or decreasing the solute solu-
bility (e.g., temperature change, antisolvent addition, pH change, salting out). The con-
centration threshold above which crystallization (nucleation) is observed is determined
by the kinetic stability of supersaturated states and is regulated by nucleation mecha-
nisms (homogenous, heterogeneous) and kinetics. The next step in crystallization is the
formation of macroscopic crystals from stable nuclei, called »crystal growth«. Crystal
growth is controlled by internal (crystal structure) and external factors (temperature, im-
purities, supersaturation, solvent type) and determines the particle morphology (12–15).
Under controlled conditions, such as solvent composition, temperature regulation,
supersaturation generation, or mixing speed, crystallized particles can simultaneously
agglomerate into spherical dense agglomerates (16, 17). The most commonly used sphe-
rical crystallization techniques are spherical agglomeration and quasi-emulsion solvent
diffusion. In both processes, a good solvent that dissolves the compound to be crystal-
lized is used, and a poor solvent that acts as an antisolvent is used to generate the re-
quired supersaturation. Other extensions of these techniques are crystallo-co-agglomer-
ation and the ammonia diffusion system.
Spherical agglomeration
Various authors give this kind of agglomeration process different names (18). It is
usually called »spherical agglomeration« when the process is aimed at producing final
particulate material with special characteristics (19). When its aim is to facilitate manu-
facturing processes such as filtration or handling, the term »agglomeration in suspen-
sion« is used (18, 20). The term »selective agglomeration« is employed when it is used to
separate a solid component from a mixture (21) or »oil(-assisted) agglomeration« when
oil or some other organic liquid is used as a »bridging« liquid to facilitate the agglomer-
ation process (22, 23). In addition to being used in producing spherical particles of phar-
maceutical powders with improved physical properties, this kind of agglomeration is
also useful for selective collection of one dispersed phase among many, such as may be
desired in coal purification and mineral beneficiation (24, 25) or de-inking toner on prin-
ted paper for secondary fiber recovery (26), where hydrophobic particles are agglomer-
ated to a sufficient size and then effectively removed by filtration or air flotation.
In the spherical agglomeration method, a solution of a compound in a good solvent
is poured into the poor solvent, which is miscible with the good solvent. The affinity be-
tween the solvents must be stronger than the affinity between the good solvent and the
compound, which causes immediate precipitation of crystals. In the spherical agglomera-
tion method, a third solvent called the »bridging liquid« is also added in a smaller amount
and acts as an interparticle binder that promotes agglomeration. The bridging liquid, which
should not be miscible with the poor solvent and should wet the precipitated crystals,
collects the crystals suspended in the system by forming liquid bridges between the cry-
stals due to capillary negative pressure and interfacial tension at the solid-liquid inter-
face (Fig. 1). Surfactants are usually avoided because the strength of liquid bridges is
proportional to the interfacial tension between the bridging liquid and the solid (26).
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Some authors have reported that the amount of bridging liquid has an impact on
particle size distribution, but there is no general rule regarding how the quantity of brid-
ging liquid affects the size of agglomerates and it seems to vary on a case-by-case basis.
Some researchers report on the enlargement of agglomerates with increasing amounts of
bridging liquid (19, 28), whereas in another study of the spherical agglomeration process
the addition of a smaller amount of bridging liquid produced larger particles of acebu-
tolol (up to 1,000 mm) and vice versa a larger amount of bridging liquid produced smaller
particles (around 600 mm) (29). Katta and coworkers (30) noticed no change in the particle
size of agglomerated benzoic acid with an increased volume of bridging liquid. How-
ever, it can be concluded from other studies that if the quantity of bridging liquid is too
small, there is no significant agglomeration and when too much bridging liquid is used,
the agglomerates become soft and pasty (18, 28, 31). Some authors emphasize the impor-
tance of the choice of bridging liquid and suggest how to determine the optimal one for
spherical agglomeration. Regarding the importance of the bridging liquid wetting proper-
ties during the spherical agglomeration process, Amaro-Gonzales and Biscans (32) pro-
posed a study of the capillary uptake of liquid in a powder medium using »Washburn’s
test.« The best results during crystallization tests on lobenzarit disodium were obtained
in the presence of n-hexane, which wetted solid crystals better than other liquids. Chow
and Leung (33) postulated some rules for bridging liquid selection:
i) For compounds that are water soluble, a water-miscible organic solvent is used
as the poor solvent and salt solutions of high concentration without common
ions can be used as the bridging liquid.
ii) For compounds that are soluble in one or more organic solvents, water is em-
ployed as the poor solvent and a water-immiscible organic solvent as the bridg-
ing liquid.
iii) For compounds that are only soluble in water-miscible organic solvents, a satu-
rated aqueous solution of the compound can serve as the poor solvent and an
organic solvent as the bridging solvent.
iv) For compounds that are not sufficiently soluble in water or any organic solvent,
a water-immiscible organic solvent can act as the poor solvent and salt solu-
tions of high concentration without common ions as the bridging liquid. In ad-
dition, a binding agent such as PVP (Mr 40000) or PEG (Mr 10000) is required
for agglomeration because the powders are not sufficiently soluble in bridging
liquids to allow binding through recrystallization and fusion.
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Fig. 1. Proposed mechanism of spherical agglomeration (adapted from ref. 27).
In addition to the amount and choice of bridging liquid, other process parameters
during crystallization are also important for agglomeration kinetics and particle proper-
ties. One of the important process parameters is the agitation rate during the agglomera-
tion process. It has been shown (18, 29) that increasing stirring speed makes the agglomer-
ation process less efficient due to the shearing rate, disruptive forces, and higher proba-
bility of agglomerate collisions, which preferentially tear them apart. It has also been de-
monstrated that higher stirring speed at the same time results in decreased porosity and
greater mechanical resistance of the agglomerates produced (18). Another important pro-
cess parameter is the proportion of good solvent to poor solvent. Zhang and coworkers
have recently reported that the mean particle size of cefotaxime sodium spherical ag-
glomerates increased with an increase of the poor solvent chloroform content in the cry-
stallization system, and at the same time the particle size distribution became narrower,
which can be ascribed to higher supersaturation and more effective crystallization and
agglomeration (31). In that study, the temperature and agitation speed had no notable
impact on the agglomerated particle size, while in another study (34) higher tempera-
ture resulted in smaller particle size and increased density of agglomerated carbama-
zepine.
Quasi-emulsion solvent diffusion
The quasi-emulsion solvent diffusion (QESD) was first mentioned in 1989 by Ka-
washima and coworkers (35). The prerequisite of this method is that the interactions be-
tween the drug and the good solvent are stronger than the interactions between the
good solvent and the poor solvent. The drug is dissolved in the good solvent and when
the solution is dispersed into the poor solvent, quasi-emulsion droplets are created, even
though good and poor solvents are miscible (29). Formation of an unstable emulsion is
induced by the increase in interfacial tensions between both solvents (36). The good sol-
vent gradually diffuses out of the emulsion droplets into the outer poor solvent phase,
and the poor solvent diffuses into droplets, which reduces the solubility and eventually
causes drug crystallization inside the droplets (37, 38). Residual good solvent in the drop-
lets acts as a bridging liquid to agglomerate the generated crystals. Spherical agglome-
rates of crystals are then formed if the process parameters are set accordingly. The me-
thod is considered to be simpler than the spherical agglomeration method, but it can be
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Fig. 2. Proposed mechanism of QESD (adapted from 40).
difficult to find a suitable additive to keep the system emulsified and ensure suitable dif-
fusion of the poor solvent into the dispersed phase (Fig. 2) (39).
As previous studies have shown, solvent transfer is particularly influenced by two
basic parameters (38, 40). One of them is the difference in temperatures T1 - T2, with T1
being the temperature of the good solvent with dissolved drug before dispersion and T2
the initial temperature of the poor solvent. A smaller difference in initial temperatures
between the two phases accelerates the mass transfer of solvents and consequently the
rate of crystallization is increased. The second parameter that influences the rate of sol-
vent transfer is the initial mass ratio of good solvent to poor solvent and, as shown by
Espitalier and coworkers (41), mass transfer of the good solvent (acetone) into the poor
solvent’s phase (water) increased when the ratio between the good solvent and the poor
solvent was high. At the same time, by increasing the initial ratio of good to poor sol-
vents, the apparent density of the ketoprofen particles produced decreased. In a later
study, the median diameter of particles produced was reduced using the higher temper-
ature difference between T1 and T2 and a low ratio of good solvent to poor solvent. The
results were explained by more intense creation of supersaturation. The effect of the
overall temperature of the dispersed system on particle shape and size has been demon-
strated by Zhang and coworkers (42). At higher temperatures, the agglomerated silybin
particles were larger (0.89, 1.74, and 2.48 mm at 15, 23, and 30 °C, respectively) and more
spherical (Fig. 3) (42), which was explained by a higher diffusion rate, increased interfa-
cial tension, and higher kinetic energy of the droplets.
Some authors reported that an emulsifier must be used for the QESD method. No-
cent and coworkers (44) conducted a study of spherical crystallization of salbutamol sul-
fate using the QESD method and tested several emulsifiers with different HLB (hydro-
philic/ lipophilic balance). Only the use of the most lipophilic emulsifier in the study,
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Fig. 3. SEM images of: A) commercial silybin powder; silybin particles prepared at: B) 15 °C; C) 23
°C; D) 30 °C (from ref. 42 with permission).
Abil EM 90 (polysiloxane poly alkyl polyether copolymer; HLB = 5), yielded spherical
particles. A larger amount of emulsifiers dispersed in the poor solvent can cause a co-
alescence of particles and increase their surface roughness, whereas a lower proportion
of emulsifier increases the apparent density of particles (40). In a study by Zhang and
coworkers, a trial without surfactant resulted in relatively large spherical particles of
silybin (6.68 mm) with coarse surfaces, and trials with lower or higher concentrations of
surfactant yielded smaller particles (2.97 mm, 2.49 mm, and 2.48 mm at 0.01, 0.02, and 0.10
% SDS concentration, respectively) with narrower particle size distribution (42).
Maghsoodi and Esfehani (43) prepared naproxen agglomerates with sodium lauryl sul-
fate as a surfactant and additionally incorporated polymer Eudragit RS100 and talc (as
anti-adhesion agent) to obtain microparticles with desired dissolution properties.
Ammonia diffusion method
This is a modified spherical crystallization technique applicable to amphoteric sub-
stances, which are only soluble in acidic or alkaline aqueous solutions and insoluble in
neutral aqueous solutions or organic solvents. It is therefore impossible to agglomerate
them using conventional spherical crystallization techniques such as spherical agglom-
eration or the quasi-emulsion solvent diffusion method (44). In this technique, an aque-
ous ammonia solution is used as the good solvent and it also acts as a bridging liquid
(44, 45). The poor solvent is selected on the basis of the drug solubility in that solvent
and good miscibility with ammonia and water. Water-immiscible solvents such as hy-
drocarbons or halogenated hydrocarbons are a third component in the system, inducing
liberation of the ammonia (44). The drug is dissolved in an aqueous ammonia solution
and poured into a mixture of a poor solvent and a water-immiscible solvent. It is as-
sumed that the poor solvent enters the droplets of aqueous ammonia solution and cau-
ses drug precipitation without forming ammonium salts. Simultaneously, the ammonia
diffuses to the outer organic solvent phase and its ability as a bridging liquid becomes
weaker, which then determines the final size of agglomerates (44, 46). It is important to
find a suitable combination of solvents in order to attain a high crystallization rate. When
too much immiscible or poor solvent is applied, the resultant agglomerates form a large
solid mass or a paste and with too little solvent, drug crystals form without agglomera-
tion (46).
Crystallo-co-agglomeration
Crystallo-co-agglomeration was invented by Kadam and coworkers (47) as an at-
tempt to overcome the limitations of spherical crystallization techniques, which were re-
stricted to size enlargements of single high-dose drugs only. It is a modification of the
spherical crystallization techniques described above, in which a drug is crystallized and
agglomerated with an excipient (48, 49) or with another drug (50). Similar to spherical
agglomeration, a good solvent is used in this method to solubilize the drug, a poor sol-
vent to cause drug crystallization and the bridging liquid, which is immiscible with the
poor solvent, to form liquid bridges during the agglomeration process.
Crystallo-co-agglomeration is a complex process and is influenced by many formu-
lation and process variables. The majority of drugs are hydrophobic, soluble in organic
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solvents, and poorly soluble in water, whereas many excipients, such as diluents, dis-
integrants or glidants, are hydrophilic. Therefore the difference in the physical and che-
mical properties of drug molecules and the excipient is a major challenge in selecting a
solvent system for the crystallo-co-agglomeration and dictates the yield of the process.
Maghsoodi and coworkers (49) prepared spherical co-agglomerates with naproxen and
disintegrants, either starch or sodium starch glycolate. Acetone was used as a good solvent
and the bridging liquid, whereas water with dispersed disintegrant and a small amount
of hydroxypropyl cellulose served as a poor solvent. Disintegrant was present in the ace-
tone and aqueous phases during the agglomeration process, and so losses of disinteg-
rant could not be avoided and final yields of the agglomerates prepared were within a
range of 68 to 70 %.
Addition of various polymers such as polyethylene glycol, ethyl cellulose, or hy-
droxypropyl methylcellulose can improve the tensile strength or compressibility of ag-
glomerates. Properties of the finished product are simultaneously affected by polymer-
-induced properties such as the interfacial tension, viscosity, and the rate of vaporization
of the solvent used (51).
ADVANTAGES OF SPHERICAL CRYSTALLIZATION
Spherical crystallization techniques have been successfully applied to produce com-
pacted spherical particles of drug substances that possessed improved micromeritic pro-
perties, such as uniform shape and size of particles, lower bulk density, and better flowa-
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Table I. Pharmaceutical drugs with improved physical and mechanical properties prepared using various
spherical crystallization techniques
Drug Method Improved property Reference
Acetylsalicylic acid SA Flow properties, compactibility 17
Cefotaxime sodium SA Flow properties, compressibility 31
Lobenzarit disodium SA Particle shape and size distribution 32
Tolbutamide QESD Particle shape, flow properties 36
Bucillamine SA, QESD Flow properties, compressibility 37
Ascorbic acid SA, QESD Flow properties, compactibility 39
Salbutamol sulfate QESD Particle shape and size distribution 40
Ketoprofen QESD Flow properties, size distribution 41
Mefenamic acid ADM Flow properties, compressibility 45
Norfloxacine ADM Particle shape and size 46
Naproxen CCA Flow properties, compactibility 49
Aspartic acid SA Compressibility, compactibility 52
Naproxen QESD Compressibility, compactibility 53
SA – spherical agglomeration, QESD – quasi-emulsion solvent diffusion, ADM – ammonia diffusion method,
CCA – crystallo-co-agglomeration
bility. Consequently, the physical and mechanical properties (compressibility, compactibility)
were also improved and the particles obtained were suitable for direct tableting (Table I).
Spherical crystallization techniques can be also exploited to incorporate various ex-
cipients into agglomerates, such as colloidal silica, surfactants, or polymers. In this case
as well, the physical and mechanical properties drugs are improved and the incorpo-
rated excipients also affect the wetting properties, solubility, dissolution rate, and hence
the bioavailability of pharmaceutical drugs (Table II).
CONCLUSIONS
Spherical crystallization techniques have been widely used in the minerals industry
and are attracting increased attention for the design and manufacture of high-value pro-
ducts such as pharmaceutical drugs because they offer a solution for improving their
properties, enabling production of cost-saving direct-compression formulations and mo-
dulation of dissolution profiles for various needs. The spherical crystallization process
appears to be simple enough and inexpensive for scaling up to a commercial level, but
an extensive investigation must be carried out at the research and development stage to
attain a sufficient level of understanding regarding the controlling mechanisms of simul-
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Table II. Spherically crystallized pharmaceutical drugs with improved pharmaceutical and mechanical
properties or modified dissolution properties
Drug Method Improved property Reference
Carbamazepine SA Flow properties, compactibility, dissolution rate 34
CCA Flow properties, compressibility, dissolution rate 54
Ibuprofen QESD Flow properties, compressibility, control of drug release 35
Silybin QESD Dissolution rate 42
Naproxen QESD Flow properties, controlled release 43
CCA Flow properties, compressibility, dissolution rate 55
Ibuprofen CCA Controlled release 48
Ibuprofen,
paracetamol
CCA Flow properties, compactibility, dissolution rate 50, 51
Aceclofenac SA Flow properties, solubility, dissolution rate, bioavailability 56
Mebendazole SA Flow properties, compressibility, dissolution rate 57
Mefenamic acid SA Flow properties, compressibility, dissolution rate 58
Celecoxib SA Flow properties, compressibility, solubility, dissolution rate 59, 60
Fenbufen SA Flow properties, dissolution rate 61
Piroxicam SA Flow properties, compressibility, dissolution rate 62
Nitrendipine QESD Compressibility, solubility, dissolution rate, bioavailability 63, 64
Simvastatin SA Dissolution rate 65
SA – spherical agglomeration, QESD – quasi-emulsion solvent diffusion, CCA – crystallo-co-agglomeration
taneous crystallization and agglomeration involved in particle growth. Appropriate sol-
vents, excipients, and process parameters must be defined for each drug and specific
property desired, which may lead to prolonged experimental work, but spherical crys-
tallization could solve bioavailability issues and shorten the subsequent manufacturing
process of pharmaceutical dosage forms.
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P O V Z E T E K
Sferi~na kristalizacija zdravilnih u~inkovin
BORUT KOVA^I^, FRANC VRE^ER in ODON PLANIN[EK
Sferi~na kristalizacija je postopek izdelave ve~jih delcev z aglomeracijo manj{ih med
samo kristalizacijo. Najpogosteje uporabljeni tehniki za izdelavo tak{nih delcev sta sferi-
~na aglomeracija in kvaziemulzija z difuzijo topila. Sistem z difuzijo amoniaka in krista-
lo-ko-aglomeracija sta raz{iritvi teh dveh metod. Z nadzorovanjem procesnih parame-
trov med kristalizacijo, kot sta temperatura in hitrost me{anja, z izbiro lastnosti in mno-
`ine topil ter z izbiro pomo`nih snovi, lahko vplivamo na nastanek aglomeratov in izde-
lamo sferi~ne delce `elenih velikosti, primerne poroznosti ali trdote. Raziskovalci poro~ajo,
da imajo izdelani delci izbolj{ane preto~ne lastnosti, izbolj{ane druge fizikalne in me-
hanske lastnosti zaradi ~esar so primerni za direktno tabletiranje. V nekaterih primerih
lahko ob vgradnji ustreznih pomo`nih snovi, ki jih dodamo med procesom sferi~ne kri-
stalizacije, izbolj{amo tudi biofarmacevtske lastnosti zdravilnih u~inkovin vklju~no s po-
ve~anjem biolo{ke uporabnosti.
Kju~ne besede: sferi~na kristalizacija, aglomeracija, difuzija topila, izbolj{ane lastnosti delcev
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